Company
hVIVO PLC
LON:HVO
hVIVO plc (Ticker: HVO) is a full-service early phase Contract Research Organisation (CRO) and the global leader in human challenge trials. The Company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world’s ten largest biopharma companies. hVIVO specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in London—the largest of its kind worldwide. The Company also offers comprehensive virology and immunology laboratory services under the hLAB brand. Through its German subsidiary, CRS , hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. Its second subsidiary, Venn Life Sciences, offers Early Drug Development Consulting and Biometry services to the biopharma sector. The Group provides fully integrated drug development solutions from preclinical stages through Phase II trials, alongside patient recruitment via FluCamp . Additionally, its five clinical sites support outpatient Phase II and III trials, ensuring a seamless and efficient pathway from discovery to late-stage development.
190 stories · page 7 of 10
hVIVO publishes mosquito vaccine safety data in peer-reviewed Lancet journal
“The next steps will be to determine if these findings translate into clinical efficacy against mosquito-borne diseases"
Archive
Small Cap Feast - hVIVO, Kromek Group, Savannah Resources, and more...
10 November 2022*A corporate client of Hybridan LLP** Arranged by most recent first*** Alphabetically arrangedDish of the dayJoiners:No joiners today.Leavers:No leavers today.What’s cooking in the IPO kitchen?**One Health Group plc, intends
hVIVO wins £13.6mln RSV human challenge study contract
“We continue to see an increase in the size of our studies as new benefits of challenge study data are continually realised by both new and existing biotech and pharma clients," said CEO Yamin 'Mo' Khan
hVIVO at hub of challenge study revival says broker
The regulatory landscape for challenge studies is evolving and slowly becoming more favourably overseas
hVIVO to merge with Open Orphan to boost scale
The challenge trial charts the entire disease life cycle from healthy to sick and back to health.
hVIVO primed for profitability next year
The creator of pioneering human disease models based upon viral challenge generated revenues of £5.9mln in the six months ended June 30
hVIVO successfully conducts challenge study in older people
The process was specifically designed to provide the drug developers with an early clinical proof-of-concept platform to safely evaluate potential treatments in this vulnerable population
Archive
Proactive news snapshot: hVIVO, Statpro, Keywords Studios...
A glance at some of the day's highlights from the Proactive Investors newswire
hVIVO says joint-venture developed malaria drug kicks has moved to the clinic
AGS-v PLUS was developed by Imutex, hVIVO’s joint with a London-based company called the SEEK Group
Investments and investor services
FTSE 100 closes in the red as traders await first US rate cut since recession
Investors are expecting a cut of 0.25% in the benchmark short-term rate
Archive
Proactive news snapshot: Union Jack Oil, Ethernity Networks, hVIVO, Intosol Holdings …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Amigo friendless after broker downgrade
A look at the day's major movers, including Primorus, Staffline, Dukemount, Premier Technical Services, Babcock, Hummingbird and Serabi Gold
hVIVO hails Enanta Pharmaceuticals’ study success
The US drug developer used the UK company's London facility and its specially designed trial protocol
Investments and investor services
FTSE 100 closes higher Monday, just, as traders sit on hands
Footsie closed around 11 points higher at 7,357 at the start of the week, while mid-cap cousin FTSE 250 gained over 39 points